Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.32 |
| ▸ | RET | P07949 | 4/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.30 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4783359 | 0.91 | MAPK14 (0.35) | MAPK14NR1I2RETMETBRAF | |
| SCHEMBL4799754 | 0.81 | MAPK14 (0.37) | MAPK14NR1I2 | |
| SCHEMBL4779088 | 0.79 | DDR2 (0.38) | BRAFCTSLCTSSCTSK | |
| SCHEMBL4782271 | 0.78 | MAPK14 (0.39) | MAPK14NR1I2BRAF | |
| SCHEMBL4781871 | 0.77 | MAPK14 (0.37) | MAPK14BRAF | |
| SCHEMBL4779207 | 0.77 | NR1I2 (0.38) | NR1I2 | |
| SCHEMBL4783718 | 0.76 | LMNA (0.36) | NR1I2ALDH1A1 | |
| SCHEMBL4780940 | 0.75 | DRD2 (0.34) | NR1I2 | |
| SCHEMBL4781720 | 0.75 | MAPK14 (0.43) | MAPK14ALDH1A1 | |
| SCHEMBL4779210 | 0.75 | TEK (0.41) | NR1I2BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008021388-A1 | HETEROARYL DERIVATIVES AS CYTOKINE INHIBITORS | KEMIA, INC. (US) | 2008-02-21 | — | — | WO | disclosed |